Actively Recruiting
CD8 PET Imaging in Metastatic Solid Tumours
Led by University Medical Center Groningen · Updated on 2026-02-09
30
Participants Needed
4
Research Sites
190 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-center, single-arm trial designed to evaluate the safety and imaging characteristics of 89Zr-Df-crefmirlimab in patients with locally advanced or metastatic solid tumours prior to and during PD-1 antibody therapy.
CONDITIONS
Official Title
CD8 PET Imaging in Metastatic Solid Tumours
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at time of consent
- Histologically confirmed locally advanced or metastatic solid cancer suitable for anti-PD1 therapy
- Disease progression after first-line therapy or no better standard treatment available
- At least one lesion accessible and eligible for biopsy
- Measurable disease by RECIST v1.1 criteria
- ECOG performance status 0 or 1
- Life expectancy of at least 12 weeks
- Adequate organ and bone marrow function as defined by specific blood counts and liver/kidney function
- Signed informed consent
- Willingness and ability to comply with study procedures
- Agreement to use highly effective contraception for patients of childbearing potential
You will not qualify if you...
- Treatment with anti-cancer therapy or investigational agents within 28 days before study drug
- Untreated symptomatic brain metastases, leptomeningeal disease, or spinal cord compression
- Prior immune checkpoint inhibitor treatment
- Major surgery within 28 days before study drug or planned during study
- History of autoimmune diseases except controlled hypothyroidism or type I diabetes
- Systemic immunosuppressive medication within 4 weeks before study drug
- Prior allogeneic bone marrow or solid organ transplant
- Active infections like HIV, hepatitis B or C, tuberculosis, or immunodeficiency
- Receipt of live vaccine within 30 days before study drug
- Active infection requiring systemic antibiotics within 2 weeks before study drug
- Less than 2 weeks from recovery of documented COVID-19 infection
- Medical or psychiatric conditions impairing informed consent or study participation
- Sponsor employees or immediate family
- Positive pregnancy test or breastfeeding
- Unwillingness to use effective contraception
- Contraindications for MRI scan
- Splenic disorders or splenectomy affecting study objectives
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
VUMC
Amsterdam, Netherlands, 1081 HV
Actively Recruiting
2
University Medical Center Groningen
Groningen, Netherlands, 9713 GZ
Actively Recruiting
3
Vall d'Hebron Institute of Oncology (VHIO) / Vall d'Hebron Institute Research (VHIR)
Barcelona, Spain, 08035
Not Yet Recruiting
4
University of Cambridge
Cambridge, United Kingdom, CB2 1TN
Not Yet Recruiting
Research Team
E
Elisabeth GE de Vries, MD, PhD
CONTACT
D
Daan G. Knapen, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here